Human IL-18/IL-1F4 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB9124
Recombinant Monoclonal Antibody.
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Clone # 1072F
Product Specifications
Immunogen
E. coli-derived recombinant human IL-18/IL-1F4
Tyr37-Asp197
Accession # Q14116
Tyr37-Asp197
Accession # Q14116
Specificity
Detects human IL-18/IL-1F4 in direct ELISAs.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IL-18/IL-1F4 Antibody
IFN-gamma Secretion Induced by IL-18/IL-1F4 and Neutralization by Human IL-18/IL-1F4 Antibody.
In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog # 210-TA), Recombinant Human IL-18/IL-1F4 (Catalog # 9124-IL) stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/IL-1F4 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Human IL-18/IL-1F4 Monoclonal Antibody (Catalog # MAB9124). The ND50 is typically 0.05-0.3 µg/mL.Applications for Human IL-18/IL-1F4 Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize IL‑18/IL‑1F4-induced IFN‑ gamma secretion in the KG‑1 human acute myelogenous leukemia cell line. Novick, D. et al. (1999) Immunity 10(1):127. The Neutralization Dose (ND50) is typically 0.05‑0.3 µg/mL in the presence of 10 ng/mL Recombinant Human IL‑18/IL‑1F4 and 20 ng/mL Recombinant Human TNF‑ alpha.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-18/IL-1F4
References
- Dinarello, C.A. et al. (2013) Front. Immunol. 4:289.
- Smith, D.E. (2011) J. Leukoc. Biol. 89:383.
- Gu, Y. et al. (1997) Science 275:206.
- Torigoe, K. et al. (1997) J. Biol. Chem. 272:25737.
- Cheung, H. et al. (2005) J. Immunol. 174:5351.
- Novick, D. et al. (1999) Immunity 10:127.
- Fehniger, T.A. et al. (1999) J. Immunol. 162:4511.
- Yoshimoto, T. et al. (1998) J. Immunol. 161:3400.
- Yoshimoto, T. et al. (2000) Nat. Immunol. 1:132.
- Kroeger, K.M. et al. (2009) J. Leukoc. Biol. 86:769.
- Lalor, S.J. et al. (2011) J. Immunol. 186:5738.
- Li, J. et al. (2004) Cell. Immunol. 227:103.
- Elbim, C. et al. (2005) Clin. Diagn. Lab. Immunol. 12:436.
- Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.
- Ushio, S. et al. (1996) J. Immunol. 156:4274.
- Gaggero, A. et al. (2004) Oncogene 23:7552.
- Bellora, F. et al. (2012) Eur. J. Immunol. 42:1618.
Long Name
Interleukin 18
Alternate Names
IGIF, IL-1F4, IL-1g, IL18
Gene Symbol
IL18
UniProt
Additional IL-18/IL-1F4 Products
Product Documents for Human IL-18/IL-1F4 Antibody
Product Specific Notices for Human IL-18/IL-1F4 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...